Suzanne Freitag, MD
Ophthalmology · Boston, MANPI 1710974464
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 85.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $40,927 and has fallen 50.2% since, to $20,384 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $1179.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$82K
- H. Lundbeck A S$9K
- Argenx US, Inc.$1K
- Janssen Research & Development, LLC$1K
- Medtronic$615
- W. L. Gore & Associates, Inc.$520
- plus $850 from 9 others
What the payments were for
- Consulting fees$51,89654%
- Speaking & faculty fees$30,35432%
- Travel & lodging$11,24712%
- Food & beverage$2,0312%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 60 | $82,066 |
| H. Lundbeck A S | 4 | $9,085 |
| Argenx US, Inc. | 2 | $1,200 |
| Janssen Research & Development, LLC | 1 | $1,200 |
| Medtronic | 1 | $615 |
| W. L. Gore & Associates, Inc. | 1 | $520 |
| Mallinckrodt Hospital Products Inc. | 3 | $305 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $208 |
| Biotissue Holdings Inc. | 1 | $188 |
| Tempus AI, Inc | 1 | $30 |
| Lilly USA, LLC | 1 | $26 |
| LNHC, Inc | 1 | $24 |
| UCB, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$62,502
- Product in Development$520
- ACTHAR$115
How this compares
$95,536 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 46 | $480 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Nimesh PatelBoston$94K
- Michael RaizmanBoston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.